InBio Ltd . _ _____ _

InBio LtdInBio Ltd..______________________________________________________________________

Akadeemia tee 21 • Tallinn • 12680 Estonia • www.inbio.ee • e-mail: [email protected] • Reg.nr.:10565826

InBio LtdInBio Ltd..

ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS



•Established in Tallinn, 1999

•General business idea: to develop new effective and selective skin cancer therapeutics and diagnostics.

•The company was initiated by a group of scientists of National Institute of Chemical Physics and Biophysics and Karolinska Institute, Sweden

Facts on InBio

1999 2000 2001Turnover 10000 225000 190000

Profit before taxes -2000 19000 8000

Equity 3300 3300 3300Employees 2 4 7

Financial results (EUR):





•The foreseen products of our company are prototypes of new anti-cancer drugs that are characterised by:

-high degree of selectivity -efficient delivery

•Cancer is the second most common cause of death in the developed world

•The limits of usefulness are being approached for conventional therapies and further advances will require principally new approaches

Background for product development



•Antibodies are made by a class of white blood cells •They are naturally present in the blood •Biological function is to perform defence functions•Each antigen causes the formation of a specific antibody•Recombinant DNA technology allows the engineer antibodies•It is possible to produce complete antibodies in cell culture systems.

What is antibody?



•Can be rationally designed and easily made•Can be engineered to add fragmenmts that enhance their therapeutic potential•Have no intrinsic toxicity as based on the natural molecules• Monoclonal antibodies (mAbs)will not fail at the drug safety testing (phase I clinical trial stages)•Technology is now advanced enough for therapeutic applications of mAbs

Reasons to use antibodies in drug development



• Our technology combines two different platforms:

1. Monoclonal antibodies against cancer-specific antigens

2. Modification of antibody sequence to make these mAbs membrane permeable

• Such approach helps to utilise intracellular cancer-specific targets that can not be usually reached

• Focus on skin cancer, first targets are GLI proteins

What is new in our technology ?



What are GLI proteins?

• GLI proteins are gene switches

• GLI proteins are involved in development and lead cells to divide

• Abnormal activation of GLI proteins lead to

cancer• GLI proteins represent an attractive target for anticancer drug development

Gene switch turned on Cancer develops

Cancer development inhibited





Cell penetrating peptides (CPPs)

•Family of peptides capable to penetrate cellular membranes

•We can transport the following molecules into cells using CPP technology:

-other peptides -nucleic acids-proteins e.g. antibodies



World antibody market:

•Currently more than 200 monoclonal antibodies are in development •Targeted disorders include cancer, heart disease, infectious diseases and autoimmune diseases

•Market is still in its inception stage, •Market size estimated at nearly $2.8 billion in 1999, •Market forecast growth to almost $9.8 billion in 2004.

•Expected therapeutic antibody average annual growth rate is projected at 21,8% •Diagnostic/therapeutic antibody AAGR will grow at fast nearly 50% rate

Main Target Markets for InBio:•Scandinavian Market•U.S. market



Timing and positioning

•Antibody based drugs are in the position of significant commercial growth

•InBio enters the market at the moment when all developers seek for new approaches

•InBio has new technology to make antibodies more effective

•InBio has involved outstanding specialists from all fields that are required to accomplish our business plan



Will invest in profitable business at evolving market

Will invest in area that is significantly improving the well-being of the mankind

Will get possession rights of a unique know-how and new technologies that will realise in new type of therapeutic and diagnostic tools

•Benefits for the investor:

Documents

InBio Ltd . _ _______________ ______________ _____

InBio Ltd . _ _____ _